CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex

International Journal of Surgery

Volumn 11, Issue 7, 2013, Pages 549-553

  Alves, Markênia Kélia Santos ^a   Faria, Mário Henrique Girão ^a   Neves Filho, Eduardo Henrique Cunha ^a   Ferrasi, Adriana Camargo ^b   Pardini, Maria Inês de Moura Campos ^b   de Moraes Filho, Manoel Odorico ^a   Rabenhorst, Silvia Helena Barem ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Age; Astrocytic tumors; CDKN2A Methylation; Expression; P16

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ASTROCYTOMA; CHILD; DNA EXTRACTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; SCHOOL CHILD; SEX DIFFERENCE;

AGE; ASTROCYTIC TUMORS; CDKN2A METHYLATION; EXPRESSION; P16;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; STATISTICS, NONPARAMETRIC;

EID: 84880329284     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2013.05.030     Document Type: Article

References (36)

1. Schneider T., Mawrin C., Scherlach C., Skalej M., Firsching R. Gliomas in adults. Dtsch Arztebl Int 2010, 107:799-808.
2. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
3. Natsume A., Kondo Y., Ito M., Motomura K., Wakabayashi T., Yoshida J. Epigenetic aberrations and therapeutic implications in gliomas. Cancer Sci 2010, 101:1331-1336.
4. Giacinti C., Giordano A. RB and cell cycle progression. Oncogene 2006, 25:5220-5227.
5. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. NEngl J Med 2000, 343:1350-1354.
6. Ohgaki H., Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009, 100:2235-2241.
7. Hegi M.E., Murat A., Lambiv W.L., Stupp R. Brain tumors: molecular biology and targeted therapies. Ann Oncol 2006, 17:x191-x197.
8. Wakabayashi T., Natsume A., Hatano H., Fujii M., Shimato S., Ito M., et al. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Neurosurgery 2009, 64:455-462.
9. Yu J., Zhang H., Gu J., Lin S., Li J., Lu W., et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 2004, 4:65.
10. Zhao G.H., Li T.C., Shi L.H., Xia Y.B., Lu L.M., Huang W.B., et al. Relationship between inactivation of p16 gene and gastric carcinoma. World J Gastroenterol 2003, 9:905-909.
11. Park S.H., Jung K.C., Ro J.Y., Kang G.H., Khang S.K. 5' CpG island methylation of p16 is associated with absence of p16 expression in glioblastomas. JKorean Med Sci 2000, 15:555-559.
12. Schmidt E.E., Ichimura K., Messerle K.R., Goike H.M., Collins V.P. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer 1997, 75:2-8.
13. INK4A gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer 1997, 73:57-63.
14. De Souza Nascimento P., Maciel C.M., Kawamura M.T., Oliveira J.A., Teixeira A., Carvalho Mda G., et al. Molecular analysis of CDKN2 (p16) in gliomas associated with clinical data. Oncol Rep 2001, 8:1039-1043.
15. Arifin M.T., Hama S., Kajiwara Y., Sugiyama K., Saito T., Matsuura S., et al. Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas. JNeurooncol 2006, 77:273-277.
16. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P.L., et al. Genetic pathways to glioblastoma: a population based study. Cancer Res 2004, 64:6892-6899.
17. Evangelou K., Bramis J., Peros I., Zacharatos P., Dasiou-Plakida D., Kalogeropoulos N., et al. Electron microscopy evidence that cytoplasmic localization of the p16 (INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas. Biotech Histochem 2004, 79:5-10.
18. Ferrasi A.C., Pinheiro N.A., Rabenhorst S.H., Caballero O.L., Rodrigues M.A., de Carvalho F., et al. Helicobacter pylori and EBV in gastric carcinomas: methylation status and microsatellite instability. World J Gastroenterol 2010, 16:312-319.
19. Faria M.H., Goncalves B.P., Patrocinio R.M., Moraes-Filho M.O., Rabenhorst S.H. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology 2006, 26:519-527.
20. McCarty K.S., Miller L.S., Cox E.B., Konrath J., McCarty K.S. Sr Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985, 8:716-721.
21. Zang J.J., Xie F., Xu J.F., Qin Y.Y., Shen R.X., Yang J.M., et al. p16 gene hypermethylation and hepatocellular carcinoma: a systematic review and meta-analysis. World J Gastroenterol 2011, 17:3043-3048.
22. Alves M.K., Lima V.P., Ferrasi A.C., Rodrigues M.A., De Moura Campos Pardini MI., Rabenhorst S.H. CDKN2A promoter methylation is related to the tumor location and histological subtype and associated with Helicobacter pylori flaA(+) strains in gastric adenocarcinomas. APMIS 2010, 118:297-307.
23. Fan X., Munoz J., Sanko S.G., Castresana J.S. PTEN, DMBT1, and p16 alterations in diffusely infiltrating astrocytomas. Int J Oncol 2002, 21:667-674.
24. Costello J.F., Berger M.S., Huang H.S., Cavenee W.K. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996, 56:2405-2410.
25. Fueyo J., Gomez-Manzano C., Bruner J.M., Saito Y., Zhang B., Zhang W., et al. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 1996, 13:1615-1619.
26. Tirabosco R., De Maglio G., Skrap M., Falconieri G., Pizzolitto S. Expression of the Polycomb-Group protein BMI1 and correlation with p16 in astrocytomas an immunohistochemical study on 80 cases. Pathol Res Pract 2008, 204:625-631.
27. Reifenberger G., Collins V.P. Pathology and molecular genetics of astrocytic gliomas. JMol Med (Berl) 2004, 82:656-670.
28. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002, 8:1153-1160.
29. Watanabe T., Nakamura M., Yonekawa Y., Kleihues P., Ohgaki H. Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4A genes in oligodendrogliomas. Acta Neuropathol 2001, 101:185-189.
30. Li Q., Jedlicka A., Ahuja N., Gibbons M.C., Baylin S.B., Burger P.C., et al. Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene 1998, 16:3197-3202.
31. Mann M., Cortez V., Vadlamudi R.K. Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy. Cancers (Basel) 2011, 3:1691-1707.
32. Gonzalo S. Epigenetic alterations in aging. JAppl Physiol 2010, 109:586-597.
33. Kouzmenko A., Ohtake F., Fujiki R., Kato S. Hormonal gene regulation through DNA methylation and demethylation. Epigenomics 2010, 2:765-774.
34. Calvanese V., Lara E., Kahn A., Fraga M.F. The role of epigenetics in aging and age-related diseases. Ageing Res Rev 2009, 8:268-276.
35. Csaba G. Hormonal imprinting: phylogeny, ontogeny, diseases and possible role in present-day human evolution. Cell Biochem Funct 2008, 26:1-10.
36. Ahuja N., Issa J.P. Aging, methylation and cancer. Histol Histopathol 2000, 15:835-842.